

Reports of stakeholder meetings from EAHP Congress 2016

Wednesday 16th March 2016

**Professor Ilko Getov, Vice President of the Pharmaceutical Group of the European Union (PGEU)
1530-1615**

The Falsified Medicines Directive

Professor Getov very early into the meeting requested to discuss the Falsified Medicines Directive with EAHP and his concern about missing hospital pharmacy representation within the European Medicines Verification Organisation (EMVO). PGEU would like to help EMVO achieve better hospital pharmacy representation. **The offer was therefore made for a focused meeting in Brussels between secretariat and Board level representations to take this issue further.**

ACTION: OFFER OF MEETING TO BE DISCUSSED AND PROGRESSED IF ACCEPTABLE

In reference to the Supply Chain Actors initiative on shortages, both organisations agreed that getting the definition of shortage correct was of utmost importance. Both organisations are resistant to industry's risk-based proposal.

PGEU will host its annual symposium in the Hague 8th-9th June 2016, to which EAHP is welcomed to attend and participate.

ACTION: TO CONSIDER EAHP REPRESENTATION TO PGEU JUNE 2016 MEETING

**Rahul Singhal, NHS England
1745-1815**

Kees Neef and Richard Price met with Rahul Singhal of NHS England, and Tony West.

Mr Singhal is a 'clinical fellow' working for NHS England's Chief Pharmaceutical Officer on the matter of 7 day a week clinical pharmacy services. Tony West explained the background to the project as stemming from the UK Government's election manifesto pledge to create a '7 day a week' health service. In practice, this meant services being available every day a week and not just Monday to Friday. Tony considered this an important issue for hospital pharmacy. If clinical pharmacy services are important to patient safety then why should they not be available 7 days a week? Tony also considered this was relevant to EAHP statement implementation (section 4 – clinical pharmacy services).

Mr Singhal explained he is creating a report for the Chief Pharmaceutical Officer covering all matters concerned with 7 day a week clinical pharmacy services and wished to include a European dimension i.e. what was occurring elsewhere, lessons to share, potential technology enablers, risk stratification tools.

Kees suggested contact with several Dutch colleagues in Nijmegen and Rotterdam. Kees also considered a small survey to a select audience might be appropriate. This

may have fit with future survey activity in relation to implementation of Section 4 of the European Statements.

ACTION: KEES NEEF TO PROVIDE DUTCH COLLEAGUE CONTACT DETAILS

ACTION: FOLLOW UP TO OCCUR ON SURVEY SUGGESTION

**Dr Silvia Ravera, Scientific Officer, EDQM
1815-1845**

Pharmaceutical Care Indicators

EAHP asked for an update on this EDQM workstream. The relevant Committee of Experts will meet in April 2016 in order to advance a resolution on the topic, very likely to promote the use of indicators for this activity.

Falsified Medicines Directive

EDQM will commence its new auditing role of EMVO soon. Other EDQM activities in this area include [the Medicrime convention](#) in which FIP and EGA participate. EAHP would always be welcome to be involved.

Pharmacopeia for paediatric medicines

EDQM has created a working party to form such a pharmacopeia. The group is examining monographs for paediatric formulations in order to improve what's in place. There is scope for hospital pharmacy involvement in this activity, for example:

- bringing existing monographs to EDQM's attention,
- nominating individuals to the working party,
- nominating a person for virtual correspondence
- making presentations to the working party

EAHP representatives at the meeting mentioned examples from Ireland and the Netherlands (national children's formulary) that could be of interest to EDQM.

Production and reconstitution

EDQM is working on a fresh resolution in the area of medicines production, this time focused on reconstitution. This will include defining responsibilities, issues such as labeling and risk management.

EDQM is not working particularly in the sphere of medicines shortages, apart from a small project examining the impact upon patients when using medicines with packages and leaflets from other countries.

ACTION: TO CONSIDER EAHP INVOLVEMENTS WITH ABOVE DESCRIBED ACTIVITIES

ACTION: TO APPROACH ON STATEMENT ENDORSEMENT

Sascha Marshang, Policy Manager for Health Systems, European Public Health Alliance (EPHA) 1845-1915

Antimicrobial resistance

Sascha described the recent streamlining and focusing of activities at EPHA, which has included making antimicrobial resistance a campaign priority. Sascha shared some of his reflections on the policy area. While the Dutch Presidency of the EU and

others are giving attention to the “One Health” concept, Sascha considers there to be a missing focus on multidisciplinary approaches, including those that involve hospital pharmacy. He is also interested in exploring why some approaches appear not to be yielding the intended results. What are the barriers to behavior change? In general though, at the political level, attention on prudent use appears to be declining.

EPHA’s AMR campaign focus is on influencing the Dutch Presidency Council conclusions on the issue as well as the EU Action Plan. Campaign calls include seeking measurable targets in improved antibiotic use. Frank Jorgenson was able to give examples of achievements in Norway from use of targets. Sascha is interested to receive more information about this and other examples.

EPHA’s autumn conference (8th September) will have an AMR focus and the current theme under exploration is RESISTANCE (i.e. resistance to change). He would be interested to have a hospital pharmacy speaker involved in one of the panels, though seeking to keep commentary of a political nature rather than a technical nature given the diverse audience.

ACTION: PROVIDE SASCHA WITH HP GOOD PRACTICES ON AMR

ACTION: CONTINUE LIAISON WITH SASCHA ABOUT 8TH SEPTEMBER CONFERENCE

Thursday 17th March 2016

João José Joaquim, President, European Association of Pharmacy Technicians (EAPT) 0845-0915

Mr Joaquim was able to announce early in the meeting that EAPT is now a registered European association in Belgium. 14 countries are included within the membership including Ireland. Its next annual meeting will take in Dublin 20-21 May 2016 (starting 19th May with a welcome dinner) and EAPT would be delighted to have EAHP representation.

ACTION: EAPT TO NOW LIAISE WITH JENNIE REF POTENTIAL TECHNICIAN PROGRAMME AT EAHP CONGRESS IN CANNES IN 2017

ACTION: EAHP TO CONSIDER ATTENDENCE IN DUBLIN 20-21 MAY 2016

Beyond this EAPT are seeking to form a common understanding of pharmacy technician competencies similar to a common training framework and are submitting a funding bid to Erasmus Plus (DG Employment) to support this work. EAPT also have aspirations for a European Professional Card.

Lillian Azzopardi, President, European Association of Faculties of Pharmacy (EAFP) 0915-0945

The meeting provided and opportunity for general updates to be shared between the two organisations.

EAFP is developing a 3 day summer school to take place in early September. This will take as its focus the development of student trainers in the area of bedside care. The educational event will take place in Malta. Lillian undertook to send further details.

Lillian gave some feedback in respect to the EAHP-EPISA student science award. Student submitters very much appreciated the comments received from the EJHP editor on their submissions.

**Markus Lampert, President, European Society of Clinical Pharmacy (ESCP)
0945-1015**

New spirit of collaboration

Markus attended with two other Board Members who happened to be at the Congress. The meeting opened on the positive note that the new President and Board considered it very important that relations between EAHP and ESCP take a stronger partnership form. The membership overlap and community of interest demanded it. Both Associations were happy to make this commitment to each other.

European Statements of Hospital Pharmacy

The meeting then discussed the European Statements of Hospital Pharmacy, in which ESCP could identify common ideas and values. Markus said he believed that ESCP could fully support the statements and could see opportunities for ESCP and EAHP to work in the same direction.

EAHP discussed its approach towards implementation of the statements. On GPIs, Markus Lampert thought the risk building dual databases needed to be recognized. However, perhaps some formal of linkage/reciprocity could be formed, between EAHP's GPI database and material ESCP produces and makes available in this area. It was the mission of both organisations to conduct this kind of activity in support of professional development. The suggestion was to be returned to the EAHP Scientific Committee.

ESCP also intends to develop webinar series and saw opportunities for collaboration in this regard too e.g. jointly identified needs, potentially stemming from the statements.

ACTION: THE MEANS BY WHICH ESCP AND EAHP CAN COOPERATE ON CLINICAL PHARMACY GPI EXCHANGE AND OTHER DEVELOPMENT ACTIVITY (E.G. WEBINARS) TO BE FURTHER EXPLORED AND AGREED

ACTION: TO APPROACH ON STATEMENT ENDORSEMENT

**Eline Vandael, Board Member, Pharmaceutical Care Network Europe (PCNE)
1015-1045**

Filipa Alves da Costa, former chairperson of PCNE, from Portugal, accompanied Eline. Eline is a Phd researcher from KU Leuven. Eline gave a presentation on the background, purpose and activities of PCNE.

The Pharmaceutical Care Network Europe (PCNE) was established in 1994 by a number of European pharmaceutical care researchers. The aim of PCNE is to help to develop pharmacy along the lines of pharmaceutical care in the involved European countries through:

- stimulating pharmaceutical care and pharmacy related outcome research
- stimulating research and implementation projects;
- organizing a bi-annual working conference on pharmaceutical care and pharmacy practice research;

Its membership is currently a mixture of institutions (universities), professional associations (mostly community pharmacy) and individual members. The membership is composed of 101 institutions and 34 individual members.

Past PCNE projects were outlined, including in the fields of therapeutic outcome monitoring (led by Pharmakon in Denmark), early medication analysis (led by Prof James McElnay, Queens University Belfast), self-care (Pharmakon, Denmark) and Behavioural Pharmaceutical Care Scale (BPCS – led by McElnay, QUB).

Currently PCNE has 3 working groups conducting activities in the areas of: Drug Related Problems; Medication Review; and, Guidelines and Standards.

On Drug Related Problems, the working group is proposing changes to the existing classifications and intends to publish their proposals shortly. Validation for the proposals will be sought.

On medication review, the working group has agreed a definition for the activity: *“Medication review is a structured evaluation of patient’s medicines with the aim of optimizing medicines use and improving health outcomes. This entails detecting drug related problems and recommending interventions.”*

The working group on Guidelines & Standards is managing an inventory of existing material and is creating a basic document: “How to develop a guideline”.

PCNE has also taken on the previous “Europharm Forum Observatory” which is a knowledge database regarding pharmaceutical care, as well as an online discussion forum. This is now called “PCNE-Wiki”.

The focus of PCNE’s next working conference is the development of a core outcome set for pharmaceutical care interventions. EU funding is being sought.

The meeting discussed the European Statements of Hospital Pharmacy, and the PCNE attendees were open to the prospect of PCNE considering giving endorsement.

PCNE, recognizing the emphasis within the network towards community practice, saw potential value in EAHP becoming an observer organization to the network.

ACTION: TO CONSIDER LEVEL OF EAHP INTEREST IN PCNE WORKSTREAMS (DRUG RELATED PROBLEMS; MEDICATION REVIEW; GUIDELINES AND STANDARDS)

ACTION: TO CONSIDER PCNE’S INVITATION TO BE AN OBSERVER ORGANISATION

ACTION: TO APPROACH ON STATEMENT ENDORSEMENT

Marika Saar, Board Member, European Society for Oncology Pharmacy (ESOP)

The conversation was of a general nature. Marika already has strong familiarity with EAHP activities as a member of the Scientific Committee, and a part of the Estonian representation.

Marika updated EAHP on changes taking place with the umbrella organization the European Cancer Organisation (ECCO) which seeks to represent the range of different cancer healthcare professionals (e.g. medical oncologists, paediatric oncologists, oncology nurses, oncology pharmacists). ESMO, the representatives of medical oncologists, has broken off previous arrangements on conferencing, and will be operating with more independence.

Marika described the ESOP “EPIC” project <https://epicprojectesop.wordpress.com/>. The goals of the project are *“to improve the quality of oncology patient counselling by pharmacists and to improve patients understanding of their pharmacotherapy.”* The project will survey the current situation and problems at dispensing of oral anticancer drugs in the EU. Based on the results optimal post-graduate education for pharmacists about oncology topics will be designed as well as IT-tools that assist the pharmaceutical counselling process. The project is receiving funding via the EU Health Programme. ESOP is coordinating the project, with the 3 main other partners being the German Society of Oncology Pharmacy, the Estonian Society of Hospital Pharmacy, and the Slovene Chamber of Pharmacy.

The meeting discussed shortages, and it was clear synergy of interest between ESOP and EAHP existed on this topic. ESOP representatives would be participating in the COST Action.

Marika also expressed concerns about potential impacts on oncology pharmacy practice from the Falsified Medicines Directive.

The meeting ended with a brief description of some of the potential European regulatory threats that EAHP identify in the area of oncology pharmacy, including pressure on pharmacy production procedures via the ECJ Abcur judgement, and pressure being placed on the Commission in relation to off label use practices. There is also a prospect of further review of orphan drug regulation at the EU level.

Marika considered that ESOP endorsement for the European Statements of Hospital Pharmacy should be possible.

ACTION: TO MAINTAIN EXCHANGE WITH ESOP ON SHORTAGES, FMD, PRODUCTION ISSUES, ORPHAN DRUG AND OFF LABEL REGULATION MATTERS

ACTION: TO APPROACH ON STATEMENT ENDORSEMENT

Pieter Dylst, Health Economics Officer, European Generic and Biosimilar Association (EGA – now retitled to “Medicines for Europe) 1315-1345

Maarten Van Baelen, Market Access Director at EGA, accompanied Pieter Dylst.

The meeting discussed in what way cooperation with EGA on topic of joint interest (shortages, barcoding etc) could be taken up. Specifically, it was examined whether the suggestion from EGA's hospital working group, of conducting a workshop, could be taken up. Amongst the suggested themes of the workshop is tendering practices, and available models. JP stated it was her preference that more organisations be involved than only EAHP and EGA. Other pharmacist organisations such as ESCP were mentioned. EAHP's April 2016 Board Meeting would consider the issue further.

The meeting also discussed the Falsified Medicines Directive. EAHP brought up the need for aggregation of barcodes to assist hospitals in meeting the scanning burden. EGA had opposed aggregation due to costs. The technical group of the European Medicines Verification Organisation (EMVO) continues to look at these issues.

ACTION: APRIL 2016 BOARD MEETING TO MAKE DETERMINATION ON PREFERRED METHOD OF COLLABORATION WITH EGA ON TOPICS OF SHARED INTEREST

Claude Farrugia, Vice President Communications, European Industrial Pharmacists Group (EIPG) 1515-1545

The meeting started with a discussion on medicines pricing. Claude considered that pressures were growing to such an extent that he could imagine a country in Europe gaining the confidence to enforce compulsory licensing at some point.

On shortages, there appeared to be mutual interest and concern between EIPG and EAHP in relation to aspects of the Supply Chain Actors Initiative, such as the definition question. Both organisations have grown skeptical as to the prospects of the initiative yielding result. Given the time and expense of attending the meetings, Claude wondered whether on occasion EAHP might represent EIPG's position. EIPG were happy to be involved in the COST Action.

On the Falsified Medicines Directive, Claude felt strongly that affiliate members to the EMVO should not have to pay. EIPG had been able to be included on EMVO's progress report mailing list however.

EIPG extended an invitation to EAHP to attend its annual meeting on 3rd, 4th and 5th June. This had been rescheduled.

Claude believed EIPG could consider endorsement of the European Statements via its governance procedures.

ACTION: TO CONTINUE LIASON ON SHORTAGES AND FMD

ACTION: TO CONSIDER INVITATION TO JUNE 2016 ANNUAL ASSEMBLY

ACTION: TO APPROACH ON STATEMENT ENDORSEMENT

Andreas Charalambous, Board Member, European Oncology Nursing Society (EONS) 1545-1615

EONS are one of the founding members of the European Cancer Organisation (ECCO) and will now assume a more prominent role in view of recent ruptures with the European Society of Medical Oncologists (ESMO). EONS structure their activity around 4 areas: Education; Research; Advocacy; and, Communication.

EONS's main current priority is further establishing recognition for the cancer nurse specialization. To support this they are currently conducting a literature review in the area.

EONS's next Congress will take place in Dublin from 17-18th October, and Andreas envisaged the possibility of EAHP involvement in the programme of some nature. The theme is "balancing healthcare needs in a changing context". More information here: <http://eonsdublin2016.com/>

Andras Sule raised Mr Charalambous's attention to a poster at the EAHP Congress dealing with contamination with cytotoxic drugs in the workplace. Andras suggested to Mr Charalambous that nurses' awareness of these issues should be raised. Mr Charalambous was open to suggestions on how this should be done.

ACTION: TO CONTINUE LIAISON ON CTF AND SHORTAGES ISSUES

ACTION: TO CONSIDER EONS INVITATION TO BE INVOLVED IN THEIR OCTOBER CONGRESS IN DUBLIN

ACTION: TO APPROACH ON STATEMENT ENDORSEMENT

**Iris Meyenburg-Altwareg, President, European Nurse Directors Association (ENDA)
1615-1645**

Mrs Meyenburg-Altwareg described her organization, a virtual network of nurse directors designed to facilitate knowledge sharing and exchange. The meeting exchanged views and thoughts on areas of joint interest such as: risk management; sharps injury; medication error; closed loop medication systems; bedside scanning; medication reconciliation; and shortages (communication to nurses).

26th-27th May 2016 Mrs Meyenburg-Altwareg will lead a session at the 2nd "Global Hospital Management and Innovation Summit" in Brussels. She appeared open to collaboration with EAHP on the subject matter.

ACTION: TO CONSIDER COLLABORATION WITH ENDA ON HOSPITAL MANAGEMENT AND INNOVATION SUMMIT

ACTION: TO APPROACH ON STATEMENT ENDORSEMENT

Friday 18th March 2016

Monika Auzinger, Research consultant, 3s

Ms Auzinger explained the project on International Sectoral Qualifications that she was involved with on behalf of DG Employment, and took EAHP through the associated questionnaire. The report will be finalized in June 2016 and is designed to assist the Commission with its news skills agenda e.g. how the European Qualifications Framework (EQF) might be made more of.

Contacts at the European Commission that they are working with include:

- Ana Carla Pereira, Head of Unit, Responsible for "Skills and qualifications" at DG Employment, Social Affairs and Inclusion
- Karin van der Sanden, Policy Officer Skills and Qualifications at European Commission DG Employment Social Affairs and Inclusion

Her consultancy are involved in other projects for the Commission in this area, including a study on the obstacles to labour mobility, which will be sent to the EQF Advisory Group.

ACTION: TO SEEK MEETING WITH DG EMPLOYMENT WHEN JP IS IN BRUSSELS IN ORDER TO GAIN MORE INFORMATION AND UNDERSTAND FIT WITH CTF PROJECT

<i>Organ.</i>	<i>Action</i>	<i>Responsible</i>	<i>Timeframe</i>
PGEU	Offer of secretariat-Board meeting in Brussels on FMD issue to be discussed and responded to	BOARD	BY END OF APRIL 2016
	To consider EAHP representation at PGEU's June 2016 meeting	BOARD	BY END OF APRIL 2016
NHS ENGLAND	To provide relevant contact details	KN	ASAP
	Follow up on targeted survey suggestion	RP and RS	BY NEXT SC MEETING (MAY 2015)
EDQM	To consider EAHP involvement in EDQM workstreams of interest	BOARD	BY END OF APRIL 2016
EPHA	Provide Sascha with good practices on AMR	RP	BY END OF APRIL 2016
	Continue liaison with Sascha about 8 th September Conference	RP	ONGOING
EAPT	EAPT and EAHP to liaise about 2017 technician section to Congress programme	JJJ and JDG	BY END OF APRIL 2016?
	To consider attendance at EAPT event in Dublin 201-21 May 2016	JP	BY END OF APRIL 2016
EAFP	To approach for Statement endorsement		Timing: new implementation director
ESCP	Means by which ESCP and EAHP	Board and	Mid May 2016

Organ.	Action	Responsible	Timeframe
	can cooperate on clinical pharmacy GPI exchange and other development activity to be further explored and agreed	EAHP SC	
	To approach for Statement endorsement		Timing: new implementation director
PCNE	To consider EAHP involvement in PCNE workstreams of interest	Board	End of April 2016
	To consider PCNE's invitation to be an observer organization	Board	End of April 2016
	To approach for Statement endorsement		Timing: new implementation director
ESOP	Maintain exchange on shortages, FMD, production issues, orphan drug and off label matters	Board and secretariat	Ongoing
	To approach for Statement endorsement		Timing in discussion with new implementation director
Medicines for Europe	To determine method of collaboration on topics of shared interest	Board	End of April 2016
EIPG	Continue liaison on shortages and FMD	RP	Ongoing
	Consider invitation to June GA	Board	End of April 2016
	To approach for Statement endorsement		Timing: new implementation director
EONS	Continue liaison on shortages and CTF issues	RP	Ongoing
	Consider October Congress invitation (Dublin)	Board	End of April 2016
	To approach for Statement endorsement		Timing: new implementation director
ENDA	Consider collaboration with ENDA on hospital management and innovation summit (May 2016)	Board	End of April 2016
	To approach for Statement endorsement		Timing: new implementation director
3s	Seek meeting with DG Employment	RP and JP	By June 2016